This research develops a targeted anti-VEGF therapy for wet age-related macular degeneration that can be injected under the skin rather than directly into the eye. In animal studies, the drug successfully reached the eye and reduced abnormal blood vessel growth, offering a safer, cheaper, and more convenient treatment for preventing blindness.

This research investigates a new targeted treatment strategy for kidney cancer by inhibiting the cancer-promoting protein PIM1 while enhancing TRAIL-mediated apoptosis. Together with the FDA-approved drug ONC201, this combination restores cancer cells' ability to self-destruct, offering a promising therapeutic approach now being evaluated in preclinical studies.

This research develops hybrid lipo-polymeric nanoparticles that overcome major limitations of current mRNA vaccine technology. The particles can be freeze-dried, rapidly loaded with mRNA, and simultaneously deliver therapeutic drugs. Their flexibility improves vaccine storage and distribution while enabling powerful combination therapies, including enhanced cancer treatments with improved survival in preclinical models.

This research investigates how aging changes blood stem cells, causing them to produce excess sticky platelets that increase the risk of heart attack and stroke. By identifying the genetic mechanisms behind this age-related shortcut, the work aims to develop therapies that reduce cardiovascular disease while improving healing in patients with low platelet counts.

This research develops orally administered nanoparticle therapies for metronomic chemotherapy in ovarian cancer. By delivering smaller drug doses directly to tumours over extended periods, it aims to reduce side effects, overcome drug resistance, improve patient quality of life, and make long-term cancer treatment easier and more effective.

This research investigates whether the diabetes drug dapagliflozin (DAPA) can be repurposed to treat metabolic dysfunction-associated steatotic liver disease (MASLD). Using laboratory models, it examines fat accumulation and NHE1 ion channel function, aiming to develop a cost-effective treatment for two closely linked metabolic diseases with one existing medicine.

This research uses a high-throughput screening platform called EpiScan to identify HIV peptides that bind strongly to MHC molecules and appear on infected cell surfaces. By discovering these immune-visible targets, the work aims to improve detection and elimination of hidden HIV reservoirs, supporting the development of future HIV therapies.

This research investigates how misfolded Islet Amyloid Polypeptide (IAPP), a protein associated with Type 2 diabetes, affects blood clot formation. Laboratory experiments showed that misfolded IAPP creates unusually dense and resilient clots. These findings may help explain elevated cardiovascular risk in diabetes and identify new targets for preventing heart attacks and strokes.

This research develops soft, tissue-like implantable sensors capable of monitoring molecular signals inside the body in real time. By combining high-performance electronics with flexible, biocompatible materials, these devices could detect inflammation, stress, or organ damage before symptoms arise, enabling earlier diagnosis and more personalized healthcare.

This research investigates macrophages, immune cells that regulate infection, tissue repair, and cancer responses. Through laboratory experiments and machine-learning models, it aims to predict macrophage function across different diseases and patients. The work could improve prognosis, guide treatments, evaluate drug safety, and forecast recovery following major illnesses and injuries.